There is a crucial need to more deeply understand the impact and etiology of bias toward persons with developmental disabilities (PWDD). A largely unstudied area of concern and possible intervention is the portrayal of PWDD in medical education. Often, medical photographs portray PWDD with obscured faces, emotionless, and posed in an undignified way.
View Article and Find Full Text PDFObjective: This pilot study aimed to assess the effectiveness of a "room of horrors" (RoH) simulation in identifying patient safety threats in a pediatric emergency department (PED) and to evaluate health care workers' (HCWs') perceptions of the experience.
Methods: We developed an RoH simulation featuring 25 potential safety hazards derived from actual PED incidents and "never events." The teams of physicians and nurses who participated in the simulation identified as many hazards as they could within a 10-minute window followed by a debriefing session during which errors were corrected and missed hazards were pointed out.
Intersectionality has emerged as an important theoretical concept for examining overlapping social hierarchies and has garnered varying interpretations and applications in scholarly discourse. To help organize varied definitions of intersectionality that are commonly used in the social sciences, we propose a typology that distinguishes between primary, pragmatic, and pluralistic intersectionality. In this typology, primary intersectionality centers on Black women and has a social inequity focus, pragmatic intersectionality includes various groups with flexible applications, and pluralistic intersectionality encompasses a broad inclusion of categorizations without an inequity focus.
View Article and Find Full Text PDFObjectives: The objective of our study was to benchmark the incidence and severity of lorlatinib-related weight gain and dyslipidaemia in a real-world context, to guide future therapeutic strategies to mitigate these toxicities.
Methods: We conducted a retrospective, observational analysis of patients with ALK and ROS1-positive NSCLC at a single institution in the UK who were commenced on lorlatinib from 11/2016 to 11/2022. Non-small cell lung cancer (NSCLC) patients prescribed lorlatinib were identified through institutional electronic pharmacy records.